Nothing Special   »   [go: up one dir, main page]

Fry, 2014 - Google Patents

Cell separation and cryopreservation of cord blood fractions for immunotherapeutic applications

Fry, 2014

View PDF
Document ID
5928530303322359178
Author
Fry L
Publication year
Publication venue
PQDT-Global

External Links

Snippet

Abstract In 2008 Anthony Nolan opened the UK's first public umbilical cord blood (CB) bank (Anthony Nolan Cell Therapy Centre, ANCTC) in which CB is stored for haematopoietic stem cell (HSC) transplantation. Due to strict quality thresholds, the majority of units are not …
Continue reading at irep.ntu.ac.uk (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes

Similar Documents

Publication Publication Date Title
Schneidawind et al. Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality
Golab et al. Challenges in cryopreservation of regulatory T cells (Tregs) for clinical therapeutic applications
US12011461B2 (en) Compositions and methods of hematopoietic stem cell transplants
Gołąb et al. Cell banking for regulatory T cell-based therapy: strategies to overcome the impact of cryopreservation on the Treg viability and phenotype
US20150353890A1 (en) Compositions and methods for expansion of embryonic hematopoietic stem cells
Milward et al. Multiple unit pooled umbilical cord blood is a viable source of therapeutic regulatory T cells
AU2022215291A9 (en) Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
Golfier et al. Fetal bone marrow as a source of stem cells for in utero or postnatal transplantation
Fry Cell separation and cryopreservation of cord blood fractions for immunotherapeutic applications
Zhang et al. An innovative method to generate a Good Manufacturing Practice–ready regulatory T-cell product from non-mobilized leukapheresis donors
Pereira‐Cunha et al. Umbilical cord blood CD 34+ stem cells and other mononuclear cell subtypes processed up to 96 h from collection and stored at room temperature maintain a satisfactory functionality for cell therapy
Oh et al. T Cell–Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model
WO2024107410A1 (en) Cd39 selection for cytotoxicity of genetically engineered t regulatory cells
Rostami et al. Immunological Properties of Manipulated Hematopoietic Stem Cell Grafts
Taher Examining the role of lymphocytes in health and in neonatal encephalopathy and the influence of mucosal associated T cells on B cell functions
Diamond et al. Dmitri Negorev1, Ulf H. Beier2, Tianyi Zhang3, Jon G. Quatromoni4, Pratik Bhojnagarwala4, Steven M. Albelda5, Sunil Singhal4, Evgeniy Eruslanov5, Falk W. Lohoff6, Matthew H. Levine7
KR20220020277A (en) Compositions and methods for improving treatment outcomes for patients with hematological malignancies using expanded stem cell products
Lowdell et al. Processing of cells for transplantation
McKAY A Cryopreservation Protocol to Retain T Cell Function and Viability for Use in Donor Leukocyte Infusion
Singh Phenotypic and functional characterisation of myeloid and plasmacytoid dendritic cells
김병수 The Role of Regulatory T Cells Expanded by Anti-DR3 Antibody for Alleviation of Acute Graft-versus-Host Disease
Exley et al. v ledger en technical support and Pr. O. Spertini for helpful